Methods and compositions comprising thalidomide for treatment of fibromyalgia

Details for Australian Patent Application No. 2004283716 (hide)

Owner Celgene Corporation

Inventors Faleck, Herbert; Zeldis, Jerome B.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004283716

PCT Pub. Number WO2005/039497

Priority 60/514,548 24.10.03 US

Filing date 22 October 2004

Wipo publication date 6 May 2005

International Classifications

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/19 (2006.01)

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/497 (2006.01)

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

A61K 31/60 (2006.01) - Salicylic acid

A61K 31/70 (2006.01) - Carbohydrates

Event Publications

1 June 2006 PCT application entered the National Phase

  PCT publication WO2005/039497 Priority application(s): WO2005/039497

20 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004283717-Methods of treating cancer with HDAC inhibitors

2004283710-Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives